Compare · DXCM vs VTAK
DXCM vs VTAK
Side-by-side comparison of DexCom Inc. (DXCM) and Catheter Precision Inc. (VTAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and VTAK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $31.08B.
- DXCM has hit the wire 13 times in the past 4 weeks while VTAK has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for VTAK).
- Company
- DexCom Inc.
- Catheter Precision Inc.
- Price
- -
- -
- Market cap
- $31.08B
- -
- 1M return
- -5.08%
- -
- 1Y return
- +42.43%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- 2018
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest VTAK
- SEC Form 8-K filed by Catheter Precision Inc.
- SEC Form 8-K filed by Catheter Precision Inc.
- SEC Form 8-K filed by Catheter Precision Inc.
- SEC Form 8-K filed by Catheter Precision Inc.
- Catheter Precision Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Catheter Precision to Change its Name and Ticker Symbol to Flyte Aviation and “VJET” and Effect 1-for-10 Reverse Stock Split, Monday, October 5, at Market Open
- Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival
- Catheter Precision Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil
- Flyte Partners With Christian Cowan for New York Fashion Week, Expanding Its Presence Across Global Luxury Brands